 Sarah Faubel
Concepts (445)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 85 | 2025 | 777 | 15.840 |
Why?
| | Kidney | 24 | 2024 | 1306 | 3.020 |
Why?
| | Interleukin-6 | 17 | 2023 | 712 | 2.860 |
Why?
| | Ischemia | 12 | 2024 | 394 | 2.580 |
Why?
| | Reperfusion Injury | 8 | 2023 | 264 | 2.410 |
Why?
| | Acute Lung Injury | 6 | 2021 | 264 | 2.110 |
Why?
| | Sepsis | 10 | 2025 | 562 | 2.050 |
Why?
| | Lung Injury | 6 | 2017 | 199 | 1.880 |
Why?
| | Mice, Inbred C57BL | 36 | 2024 | 5268 | 1.850 |
Why?
| | Cardiac Surgical Procedures | 10 | 2020 | 493 | 1.670 |
Why?
| | Renal Replacement Therapy | 10 | 2023 | 87 | 1.650 |
Why?
| | Water-Electrolyte Imbalance | 5 | 2020 | 39 | 1.510 |
Why?
| | Nephrectomy | 7 | 2021 | 158 | 1.510 |
Why?
| | Cardio-Renal Syndrome | 2 | 2023 | 12 | 1.470 |
Why?
| | Interleukin-10 | 6 | 2017 | 298 | 1.240 |
Why?
| | Cytokines | 14 | 2021 | 1984 | 1.240 |
Why?
| | Creatinine | 12 | 2020 | 478 | 1.140 |
Why?
| | Pneumonia | 4 | 2021 | 600 | 1.080 |
Why?
| | Metabolome | 4 | 2024 | 319 | 1.040 |
Why?
| | Caspase 1 | 12 | 2014 | 141 | 1.030 |
Why?
| | Biomarkers | 19 | 2025 | 3874 | 1.010 |
Why?
| | Interleukin-18 | 11 | 2019 | 236 | 1.010 |
Why?
| | Mice | 46 | 2024 | 16574 | 1.010 |
Why?
| | Postoperative Complications | 9 | 2020 | 2456 | 1.010 |
Why?
| | Oxidative Stress | 3 | 2024 | 1181 | 1.010 |
Why?
| | Kidney Failure, Chronic | 5 | 2025 | 540 | 0.980 |
Why?
| | Energy Metabolism | 4 | 2024 | 831 | 0.960 |
Why?
| | Disease Models, Animal | 18 | 2024 | 3936 | 0.880 |
Why?
| | Exploratory Behavior | 1 | 2024 | 86 | 0.880 |
Why?
| | Lipocalins | 3 | 2019 | 36 | 0.870 |
Why?
| | Azotemia | 1 | 2023 | 7 | 0.860 |
Why?
| | Lipocalin-2 | 7 | 2023 | 75 | 0.830 |
Why?
| | Clinical Clerkship | 1 | 2024 | 95 | 0.820 |
Why?
| | Animals | 56 | 2024 | 34487 | 0.800 |
Why?
| | Glutathione | 1 | 2024 | 340 | 0.790 |
Why?
| | Body Fluids | 2 | 2020 | 62 | 0.790 |
Why?
| | Tissue Inhibitor of Metalloproteinase-2 | 4 | 2019 | 15 | 0.760 |
Why?
| | Cardiopulmonary Bypass | 3 | 2019 | 192 | 0.750 |
Why?
| | Intensive Care Units | 8 | 2021 | 734 | 0.730 |
Why?
| | Kidney Function Tests | 2 | 2019 | 145 | 0.720 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 3 | 2018 | 29 | 0.720 |
Why?
| | Nephrologists | 2 | 2017 | 12 | 0.710 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2020 | 29 | 0.690 |
Why?
| | Hospital Mortality | 9 | 2020 | 844 | 0.690 |
Why?
| | Heart Diseases | 2 | 2023 | 345 | 0.670 |
Why?
| | Cisplatin | 7 | 2016 | 297 | 0.670 |
Why?
| | Liver | 3 | 2024 | 1826 | 0.670 |
Why?
| | Critical Illness | 9 | 2023 | 755 | 0.650 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2017 | 84 | 0.630 |
Why?
| | Peritoneal Dialysis | 2 | 2018 | 95 | 0.630 |
Why?
| | Adenosine Triphosphate | 2 | 2021 | 469 | 0.620 |
Why?
| | Heart Failure, Diastolic | 1 | 2019 | 21 | 0.620 |
Why?
| | Renal Dialysis | 6 | 2021 | 420 | 0.620 |
Why?
| | Male | 56 | 2025 | 62757 | 0.600 |
Why?
| | Pulmonary Edema | 1 | 2019 | 104 | 0.600 |
Why?
| | Kidney Diseases | 5 | 2021 | 370 | 0.590 |
Why?
| | Chemokine CXCL1 | 6 | 2012 | 73 | 0.580 |
Why?
| | Humans | 70 | 2025 | 128019 | 0.570 |
Why?
| | Lung | 7 | 2023 | 3745 | 0.560 |
Why?
| | Kidney Tubular Necrosis, Acute | 5 | 2015 | 26 | 0.550 |
Why?
| | Glomerular Filtration Rate | 6 | 2023 | 682 | 0.540 |
Why?
| | Interleukin-1beta | 6 | 2014 | 368 | 0.540 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2017 | 1043 | 0.520 |
Why?
| | Nephrology | 3 | 2016 | 60 | 0.520 |
Why?
| | Proteinuria | 3 | 2019 | 88 | 0.510 |
Why?
| | Hyperkalemia | 1 | 2016 | 24 | 0.510 |
Why?
| | Peroxidase | 6 | 2017 | 169 | 0.500 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2016 | 48 | 0.500 |
Why?
| | Critical Care | 4 | 2021 | 550 | 0.500 |
Why?
| | Models, Animal | 1 | 2017 | 365 | 0.480 |
Why?
| | Containment of Biohazards | 1 | 2015 | 12 | 0.480 |
Why?
| | Acidosis | 1 | 2016 | 88 | 0.480 |
Why?
| | Caspase Inhibitors | 7 | 2014 | 76 | 0.480 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 18 | 0.470 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2015 | 35 | 0.460 |
Why?
| | Losartan | 1 | 2014 | 11 | 0.460 |
Why?
| | Lisinopril | 1 | 2014 | 14 | 0.460 |
Why?
| | Neutrophil Infiltration | 4 | 2012 | 103 | 0.460 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 33 | 0.460 |
Why?
| | Respiration, Artificial | 4 | 2018 | 600 | 0.440 |
Why?
| | Chlorides | 3 | 2020 | 137 | 0.440 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2013 | 1185 | 0.440 |
Why?
| | Thrombocytopenia | 3 | 2021 | 184 | 0.440 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 198 | 0.420 |
Why?
| | Early Medical Intervention | 1 | 2013 | 57 | 0.420 |
Why?
| | Ultrasonography, Doppler | 1 | 2013 | 118 | 0.410 |
Why?
| | Severity of Illness Index | 5 | 2014 | 2703 | 0.400 |
Why?
| | Apoptosis | 10 | 2019 | 2425 | 0.400 |
Why?
| | Interleukin-8 | 2 | 2013 | 258 | 0.390 |
Why?
| | Acute-Phase Proteins | 3 | 2019 | 67 | 0.380 |
Why?
| | Kidney Tubules, Proximal | 3 | 2014 | 125 | 0.380 |
Why?
| | Developing Countries | 1 | 2013 | 285 | 0.370 |
Why?
| | Splenectomy | 1 | 2011 | 57 | 0.360 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 329 | 0.360 |
Why?
| | Heart Failure | 3 | 2024 | 2141 | 0.310 |
Why?
| | Multiple Organ Failure | 1 | 2009 | 122 | 0.310 |
Why?
| | Hepatocytes | 2 | 2020 | 213 | 0.310 |
Why?
| | Antibodies, Monoclonal | 2 | 2013 | 1354 | 0.310 |
Why?
| | Uremia | 1 | 2008 | 13 | 0.300 |
Why?
| | Macrophages, Alveolar | 1 | 2011 | 375 | 0.300 |
Why?
| | Metabolomics | 3 | 2024 | 599 | 0.300 |
Why?
| | Retrospective Studies | 15 | 2025 | 14404 | 0.290 |
Why?
| | Inflammation Mediators | 6 | 2021 | 495 | 0.290 |
Why?
| | Antineoplastic Agents | 5 | 2016 | 2041 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1356 | 0.280 |
Why?
| | Time Factors | 8 | 2019 | 6479 | 0.280 |
Why?
| | Mice, Knockout | 9 | 2021 | 2757 | 0.280 |
Why?
| | Female | 30 | 2025 | 68016 | 0.280 |
Why?
| | Endothelial Cells | 6 | 2019 | 700 | 0.280 |
Why?
| | Inflammation | 5 | 2019 | 2646 | 0.270 |
Why?
| | Endotoxins | 3 | 2013 | 215 | 0.270 |
Why?
| | Lymphocyte Depletion | 2 | 2005 | 129 | 0.250 |
Why?
| | Blood Urea Nitrogen | 4 | 2013 | 53 | 0.250 |
Why?
| | Respiratory Insufficiency | 2 | 2011 | 311 | 0.250 |
Why?
| | Delayed Graft Function | 1 | 2005 | 30 | 0.240 |
Why?
| | Prospective Studies | 5 | 2023 | 7035 | 0.240 |
Why?
| | Necrosis | 4 | 2014 | 228 | 0.240 |
Why?
| | Lung Diseases | 2 | 2009 | 713 | 0.240 |
Why?
| | Caspases | 7 | 2013 | 240 | 0.230 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 997 | 0.230 |
Why?
| | Risk Factors | 12 | 2021 | 9696 | 0.230 |
Why?
| | Autophagy | 2 | 2021 | 265 | 0.230 |
Why?
| | Macrophages | 6 | 2021 | 1460 | 0.230 |
Why?
| | Infant, Newborn | 7 | 2023 | 5688 | 0.220 |
Why?
| | Caspase 3 | 9 | 2011 | 229 | 0.220 |
Why?
| | Hepcidins | 1 | 2023 | 22 | 0.220 |
Why?
| | Predictive Value of Tests | 3 | 2014 | 1934 | 0.220 |
Why?
| | Acute-Phase Reaction | 1 | 2023 | 40 | 0.210 |
Why?
| | Intensive Care Units, Pediatric | 4 | 2020 | 201 | 0.210 |
Why?
| | Furosemide | 1 | 2023 | 39 | 0.210 |
Why?
| | Cell Membrane | 1 | 2007 | 725 | 0.210 |
Why?
| | Infant | 6 | 2018 | 8912 | 0.210 |
Why?
| | Glycolysis | 1 | 2024 | 293 | 0.200 |
Why?
| | Spleen | 2 | 2017 | 507 | 0.200 |
Why?
| | Capillary Leak Syndrome | 2 | 2012 | 12 | 0.190 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 13 | 0.190 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 19 | 0.190 |
Why?
| | Middle Aged | 15 | 2025 | 30812 | 0.190 |
Why?
| | Nephritis | 1 | 2021 | 21 | 0.190 |
Why?
| | Child, Preschool | 7 | 2020 | 10378 | 0.190 |
Why?
| | Propensity Score | 2 | 2019 | 264 | 0.180 |
Why?
| | Stroke Volume | 1 | 2024 | 588 | 0.180 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 41 | 0.180 |
Why?
| | Ureteral Obstruction | 1 | 2021 | 59 | 0.180 |
Why?
| | Kidney Tubules | 3 | 2012 | 114 | 0.180 |
Why?
| | Drug Delivery Systems | 3 | 2016 | 327 | 0.180 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2020 | 14 | 0.170 |
Why?
| | Fibrosis | 3 | 2021 | 513 | 0.170 |
Why?
| | Learning | 1 | 2024 | 393 | 0.170 |
Why?
| | Chemokine CX3CL1 | 3 | 2011 | 23 | 0.170 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 709 | 0.170 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 1408 | 0.170 |
Why?
| | Students, Medical | 1 | 2024 | 315 | 0.160 |
Why?
| | Dialysis Solutions | 1 | 2019 | 22 | 0.160 |
Why?
| | Amino Acid Chloromethyl Ketones | 4 | 2014 | 24 | 0.160 |
Why?
| | Kidney Transplantation | 1 | 2005 | 603 | 0.160 |
Why?
| | Sex Factors | 3 | 2022 | 1942 | 0.160 |
Why?
| | Biopsy, Needle | 1 | 2019 | 187 | 0.150 |
Why?
| | Aged | 10 | 2025 | 21892 | 0.150 |
Why?
| | Random Allocation | 1 | 2019 | 342 | 0.150 |
Why?
| | Norwood Procedures | 1 | 2018 | 29 | 0.150 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2023 | 374 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1482 | 0.150 |
Why?
| | Cohort Studies | 3 | 2025 | 5378 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2015 | 562 | 0.150 |
Why?
| | Delivery of Health Care | 2 | 2015 | 888 | 0.150 |
Why?
| | Milrinone | 1 | 2018 | 29 | 0.150 |
Why?
| | Curriculum | 1 | 2024 | 909 | 0.140 |
Why?
| | History, 20th Century | 1 | 2019 | 285 | 0.140 |
Why?
| | Recovery of Function | 2 | 2019 | 630 | 0.140 |
Why?
| | Feasibility Studies | 3 | 2017 | 860 | 0.140 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2018 | 117 | 0.140 |
Why?
| | Cell Line | 5 | 2021 | 2736 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1663 | 0.140 |
Why?
| | Length of Stay | 5 | 2020 | 1114 | 0.140 |
Why?
| | Clinical Competence | 1 | 2024 | 1007 | 0.140 |
Why?
| | Postoperative Care | 1 | 2018 | 235 | 0.140 |
Why?
| | Prognosis | 3 | 2014 | 3766 | 0.140 |
Why?
| | Hyaluronic Acid | 2 | 2016 | 211 | 0.140 |
Why?
| | Survival Rate | 4 | 2018 | 1870 | 0.130 |
Why?
| | Cell Cycle Checkpoints | 1 | 2017 | 95 | 0.130 |
Why?
| | Quinolines | 3 | 2014 | 154 | 0.130 |
Why?
| | CD4 Antigens | 1 | 2017 | 138 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 251 | 0.130 |
Why?
| | Mice, Mutant Strains | 3 | 2005 | 292 | 0.130 |
Why?
| | Blood Pressure | 2 | 2022 | 1711 | 0.130 |
Why?
| | Disease Progression | 4 | 2019 | 2598 | 0.130 |
Why?
| | Endotoxemia | 2 | 2008 | 82 | 0.130 |
Why?
| | Echocardiography | 1 | 2019 | 623 | 0.130 |
Why?
| | Hemodialysis Units, Hospital | 1 | 2015 | 5 | 0.120 |
Why?
| | Risk Assessment | 4 | 2019 | 3223 | 0.120 |
Why?
| | Neutrophils | 3 | 2007 | 1192 | 0.120 |
Why?
| | Patient Isolation | 1 | 2015 | 16 | 0.120 |
Why?
| | Developed Countries | 1 | 2015 | 33 | 0.120 |
Why?
| | Contraindications | 1 | 2015 | 87 | 0.120 |
Why?
| | Transforming Growth Factor beta | 2 | 2015 | 443 | 0.120 |
Why?
| | Heart | 1 | 2019 | 637 | 0.120 |
Why?
| | Ebolavirus | 1 | 2015 | 34 | 0.120 |
Why?
| | Africa | 1 | 2015 | 98 | 0.120 |
Why?
| | Equipment Contamination | 1 | 2015 | 54 | 0.120 |
Why?
| | Mice, Transgenic | 5 | 2011 | 2066 | 0.110 |
Why?
| | Interleukin-1alpha | 1 | 2014 | 56 | 0.110 |
Why?
| | Delayed-Action Preparations | 1 | 2015 | 170 | 0.110 |
Why?
| | Travel | 1 | 2015 | 121 | 0.110 |
Why?
| | Up-Regulation | 1 | 2017 | 822 | 0.110 |
Why?
| | Nitric Oxide | 3 | 2008 | 881 | 0.110 |
Why?
| | Antibodies | 3 | 2012 | 392 | 0.110 |
Why?
| | Quality Improvement | 2 | 2019 | 1093 | 0.110 |
Why?
| | Oncogene Proteins | 1 | 2013 | 52 | 0.110 |
Why?
| | Anticoagulants | 2 | 2015 | 615 | 0.110 |
Why?
| | Myocardium | 1 | 2019 | 967 | 0.110 |
Why?
| | Calpain | 4 | 2006 | 55 | 0.110 |
Why?
| | Kinetics | 1 | 2017 | 1617 | 0.110 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 1994 | 0.100 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2013 | 624 | 0.100 |
Why?
| | Interleukins | 2 | 2011 | 240 | 0.100 |
Why?
| | Age Factors | 3 | 2018 | 3100 | 0.100 |
Why?
| | Workload | 1 | 2014 | 150 | 0.100 |
Why?
| | Receptors, Interleukin-8B | 1 | 2012 | 24 | 0.100 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2017 | 311 | 0.100 |
Why?
| | Albumins | 1 | 2013 | 101 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 815 | 0.100 |
Why?
| | Adolescent | 7 | 2020 | 20158 | 0.100 |
Why?
| | Podocytes | 1 | 2013 | 51 | 0.100 |
Why?
| | Hydrogels | 2 | 2016 | 634 | 0.100 |
Why?
| | Endocytosis | 1 | 2013 | 161 | 0.100 |
Why?
| | Child | 7 | 2020 | 20636 | 0.100 |
Why?
| | Disease Outbreaks | 1 | 2015 | 339 | 0.100 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 112 | 0.090 |
Why?
| | Flow Cytometry | 3 | 2011 | 1140 | 0.090 |
Why?
| | Complement Factor B | 1 | 2012 | 105 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2017 | 812 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 467 | 0.090 |
Why?
| | Trachea | 1 | 2013 | 221 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1012 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 794 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2015 | 500 | 0.090 |
Why?
| | Cold Temperature | 3 | 2011 | 153 | 0.090 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 747 | 0.090 |
Why?
| | Caspase 8 | 3 | 2005 | 48 | 0.090 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2008 | 168 | 0.090 |
Why?
| | Organ Preservation | 1 | 2011 | 92 | 0.090 |
Why?
| | Patient Selection | 4 | 2019 | 658 | 0.090 |
Why?
| | Chemokines | 2 | 2008 | 221 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 674 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 275 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2013 | 1266 | 0.080 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 263 | 0.080 |
Why?
| | Immunoblotting | 3 | 2005 | 301 | 0.080 |
Why?
| | Ultrasonography | 1 | 2014 | 708 | 0.080 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2007 | 116 | 0.080 |
Why?
| | Bleomycin | 1 | 2011 | 240 | 0.080 |
Why?
| | Patient Care Team | 1 | 2015 | 597 | 0.080 |
Why?
| | Polycystic Kidney Diseases | 2 | 2007 | 63 | 0.080 |
Why?
| | Survivors | 1 | 2013 | 462 | 0.080 |
Why?
| | Research Design | 1 | 2015 | 1034 | 0.080 |
Why?
| | Complement Activation | 1 | 2012 | 365 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 632 | 0.080 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2019 | 42 | 0.080 |
Why?
| | Monocytes | 1 | 2011 | 546 | 0.080 |
Why?
| | Macrophages, Peritoneal | 1 | 2009 | 90 | 0.080 |
Why?
| | NF-kappa B | 2 | 2013 | 649 | 0.080 |
Why?
| | Fluid Therapy | 1 | 2009 | 134 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2012 | 475 | 0.070 |
Why?
| | CD11b Antigen | 4 | 2009 | 59 | 0.070 |
Why?
| | Caspase 9 | 2 | 2004 | 55 | 0.070 |
Why?
| | Capillary Permeability | 1 | 2008 | 131 | 0.070 |
Why?
| | Receptors, Chemokine | 1 | 2007 | 45 | 0.070 |
Why?
| | Urothelium | 1 | 2008 | 37 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2019 | 3324 | 0.070 |
Why?
| | Pulmonary Fibrosis | 1 | 2011 | 377 | 0.070 |
Why?
| | Endpoint Determination | 3 | 2012 | 75 | 0.070 |
Why?
| | RNA, Messenger | 4 | 2009 | 2669 | 0.070 |
Why?
| | Cysteine Proteinase Inhibitors | 2 | 2004 | 47 | 0.070 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 89 | 0.070 |
Why?
| | Water-Electrolyte Balance | 2 | 2018 | 32 | 0.070 |
Why?
| | Mass Screening | 1 | 2015 | 1145 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 371 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2008 | 356 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2008 | 419 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1264 | 0.060 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2005 | 12 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2007 | 228 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2019 | 10110 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2008 | 809 | 0.060 |
Why?
| | Adult | 7 | 2021 | 35176 | 0.060 |
Why?
| | Survival Analysis | 2 | 2019 | 1262 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2013 | 799 | 0.060 |
Why?
| | Albuminuria | 2 | 2019 | 181 | 0.060 |
Why?
| | Pilot Projects | 3 | 2018 | 1559 | 0.060 |
Why?
| | Odds Ratio | 2 | 2018 | 1018 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2005 | 223 | 0.060 |
Why?
| | Insulin Resistance | 1 | 2013 | 1164 | 0.060 |
Why?
| | Cytosol | 1 | 2004 | 215 | 0.060 |
Why?
| | Rats | 4 | 2023 | 5199 | 0.060 |
Why?
| | Myocardial Ischemia | 1 | 2005 | 247 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2509 | 0.050 |
Why?
| | Young Adult | 3 | 2017 | 12281 | 0.050 |
Why?
| | Contrast Media | 2 | 2016 | 387 | 0.050 |
Why?
| | Colorado | 3 | 2019 | 4369 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2007 | 2337 | 0.050 |
Why?
| | Brain Ischemia | 1 | 2005 | 305 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2508 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3371 | 0.050 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 35 | 0.050 |
Why?
| | Comorbidity | 2 | 2019 | 1537 | 0.050 |
Why?
| | Sample Size | 2 | 2012 | 115 | 0.050 |
Why?
| | Kidney Glomerulus | 2 | 2013 | 107 | 0.050 |
Why?
| | United States | 3 | 2015 | 13785 | 0.050 |
Why?
| | Stroke | 2 | 2019 | 1063 | 0.050 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 80 | 0.050 |
Why?
| | Cells, Cultured | 4 | 2012 | 4006 | 0.050 |
Why?
| | Statistics as Topic | 2 | 2012 | 303 | 0.050 |
Why?
| | Platelet Count | 1 | 2021 | 82 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 58 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2023 | 801 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1227 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 499 | 0.040 |
Why?
| | Lysosomes | 1 | 2021 | 135 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 115 | 0.040 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 163 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 303 | 0.040 |
Why?
| | Bicarbonates | 1 | 2020 | 42 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 2859 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 40 | 0.040 |
Why?
| | Netrin-1 | 1 | 2019 | 10 | 0.040 |
Why?
| | Trefoil Factor-3 | 1 | 2019 | 5 | 0.040 |
Why?
| | Clusterin | 1 | 2019 | 10 | 0.040 |
Why?
| | Incidence | 2 | 2018 | 2614 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2019 | 47 | 0.040 |
Why?
| | Hospitals, University | 1 | 2019 | 176 | 0.040 |
Why?
| | Cystatin C | 1 | 2019 | 65 | 0.040 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2019 | 67 | 0.040 |
Why?
| | Age Distribution | 1 | 2019 | 369 | 0.040 |
Why?
| | Sex Distribution | 1 | 2019 | 356 | 0.040 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 106 | 0.040 |
Why?
| | Signal Transduction | 3 | 2021 | 4812 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2022 | 541 | 0.040 |
Why?
| | Hospitalization | 2 | 2018 | 2057 | 0.040 |
Why?
| | Exosomes | 1 | 2019 | 96 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 285 | 0.040 |
Why?
| | Zebrafish | 1 | 2022 | 464 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 755 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 124 | 0.030 |
Why?
| | Thoracic Surgery | 1 | 2018 | 122 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2018 | 195 | 0.030 |
Why?
| | Decision Trees | 1 | 2016 | 90 | 0.030 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 113 | 0.030 |
Why?
| | Sodium Bicarbonate | 1 | 2015 | 37 | 0.030 |
Why?
| | Free Radical Scavengers | 1 | 2015 | 80 | 0.030 |
Why?
| | Caspase 2 | 2 | 2006 | 13 | 0.030 |
Why?
| | Heterozygote | 2 | 2007 | 267 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 2 | 2005 | 117 | 0.030 |
Why?
| | Erythropoietin | 1 | 2015 | 84 | 0.030 |
Why?
| | Acetylcysteine | 1 | 2015 | 141 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 234 | 0.030 |
Why?
| | Reimbursement Mechanisms | 1 | 2015 | 84 | 0.030 |
Why?
| | Interleukin-1 | 2 | 2012 | 949 | 0.030 |
Why?
| | Protective Agents | 1 | 2014 | 36 | 0.030 |
Why?
| | Antioxidants | 2 | 2008 | 542 | 0.030 |
Why?
| | Interprofessional Relations | 1 | 2016 | 270 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 215 | 0.030 |
Why?
| | Crohn Disease | 1 | 2017 | 206 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 854 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2017 | 7029 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3039 | 0.030 |
Why?
| | Smoking | 1 | 2019 | 1459 | 0.020 |
Why?
| | Health Policy | 1 | 2015 | 351 | 0.020 |
Why?
| | Clodronic Acid | 1 | 2012 | 12 | 0.020 |
Why?
| | Cost of Illness | 1 | 2014 | 277 | 0.020 |
Why?
| | Diphtheria Toxin | 1 | 2012 | 64 | 0.020 |
Why?
| | Diet, High-Fat | 1 | 2013 | 238 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 117 | 0.020 |
Why?
| | Lung Compliance | 1 | 2011 | 45 | 0.020 |
Why?
| | Interleukin-33 | 1 | 2011 | 48 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 327 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 994 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 146 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 104 | 0.020 |
Why?
| | Postoperative Period | 1 | 2012 | 322 | 0.020 |
Why?
| | Informed Consent | 1 | 2012 | 168 | 0.020 |
Why?
| | Immunotherapy | 1 | 2015 | 586 | 0.020 |
Why?
| | Medicare | 1 | 2015 | 715 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 523 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1609 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 756 | 0.020 |
Why?
| | Collagen | 1 | 2011 | 429 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 930 | 0.020 |
Why?
| | Thiocarbamates | 1 | 2008 | 6 | 0.020 |
Why?
| | Liver Diseases | 1 | 2011 | 285 | 0.020 |
Why?
| | Chromones | 1 | 2008 | 45 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2009 | 215 | 0.020 |
Why?
| | GTP Cyclohydrolase | 1 | 2008 | 8 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1813 | 0.020 |
Why?
| | Amidines | 1 | 2008 | 16 | 0.020 |
Why?
| | Benzylamines | 1 | 2008 | 41 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2008 | 30 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2009 | 370 | 0.020 |
Why?
| | CX3C Chemokine Receptor 1 | 1 | 2007 | 19 | 0.020 |
Why?
| | Antimycin A | 1 | 2007 | 13 | 0.020 |
Why?
| | Spin Labels | 1 | 2008 | 46 | 0.020 |
Why?
| | Health Promotion | 1 | 2014 | 716 | 0.020 |
Why?
| | Renal Circulation | 1 | 2008 | 57 | 0.020 |
Why?
| | Proline | 1 | 2008 | 76 | 0.020 |
Why?
| | Cell Count | 1 | 2008 | 310 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1088 | 0.020 |
Why?
| | Morpholines | 1 | 2008 | 122 | 0.020 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2007 | 57 | 0.020 |
Why?
| | von Willebrand Factor | 1 | 2007 | 63 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 2007 | 362 | 0.020 |
Why?
| | RNA, Catalytic | 1 | 2007 | 185 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 304 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2011 | 719 | 0.020 |
Why?
| | Acrylates | 1 | 2006 | 45 | 0.020 |
Why?
| | Cysteine Endopeptidases | 1 | 2006 | 67 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2012 | 1037 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 257 | 0.020 |
Why?
| | Acute Disease | 1 | 2008 | 961 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 426 | 0.020 |
Why?
| | Cathepsin B | 1 | 2005 | 14 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2005 | 51 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2006 | 181 | 0.020 |
Why?
| | Caspase 7 | 1 | 2005 | 20 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 82 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2012 | 705 | 0.010 |
Why?
| | Fas Ligand Protein | 1 | 2005 | 59 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3009 | 0.010 |
Why?
| | Cell Survival | 1 | 2008 | 1073 | 0.010 |
Why?
| | Thermosensing | 1 | 2004 | 11 | 0.010 |
Why?
| | Kidney Cortex | 1 | 2004 | 25 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2004 | 43 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 2005 | 152 | 0.010 |
Why?
| | Microvilli | 1 | 2004 | 77 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 231 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2005 | 250 | 0.010 |
Why?
| | Mitochondrial Proteins | 1 | 2006 | 245 | 0.010 |
Why?
| | Perfusion | 1 | 2004 | 188 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5034 | 0.010 |
Why?
| | Cell Movement | 1 | 2007 | 933 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 467 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2007 | 2258 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2006 | 730 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 5353 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 844 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 628 | 0.010 |
Why?
|
|
Faubel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|